HI
Medical - Care Facilities
Bullish sentiment
The Hims crowd is loudly bullish and clearly in accumulation mode, pointing to Q2 revenue up 38% to $753M, 2.9M subscribers and 2026 guidance raised to $3.1B-$3.3B while short interest sits at multi-month highs. The dominant narrative is a peptide launch and oral TRT catalyst "potentially one month away," with holders framing the flat 10-week base as a coiled spring rather than a broken thesis.
Proven numbers
Hims & Hers runs a direct-to-consumer telehealth stack selling weight-loss, hair-loss, ED and mental-health prescriptions. Subscribers keep growing, but the regulatory backdrop and the insider tape both changed last quarter.
Where the pressure is now coming from:
• Growth is decelerating: Q2 revenue hit $753M (+38% YoY) with 2.9M subscribers, yet Q1 grew only 4% YoY — the acceleration story now hangs entirely on the peptide/GLP-1 launch actually rolling out on schedule.
• The FTC-linked class actions are a real overhang: multiple securities suits with a Nov 2 lead-plaintiff deadline all stem from the FTC lawsuit reveal — the regulatory drag has graduated into litigation risk.
• Officers are unloading at the current level: five insiders sold in the $27–30 range in September (Okupe alone dumped $1.4M) — people close to the numbers don't see the next catalyst as imminent.
The story isn't broken — 38% growth is 38% growth — but the FTC/class-action combo and the insider tape argue for range-bound until either the peptide launch delivers or the legal noise clears. What restarts it: Nov 9 print with concrete peptide guidance, or credible FTC-settlement language.
